InMed Pharmaceuticals Inc.
CNSX : IN
OTCQB : IMLFF

InMed Pharmaceuticals Inc.

October 23, 2014 06:00 ET

InMed Commences Development of Proprietary Drug Delivery System

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 23, 2014) - InMed Pharmaceuticals Inc. ("InMed") (CSE:IN)(OTCQB:IMLFF) announces it has has formed an exclusive strategic collaboration with Dr. Vikramaditya Yadav of the Department of Chemical and Biological Engineering at the University of British Columbia to develop a targeted drug delivery system.

The development process is focussing on a nanoparticle-based delivery system for our current and future therapies. The delivery system is currently under investigation in in vitro and in vivo animal models. The highly lipophilic nature of cannabinoids demands the development of an innovative and efficient delivery system.

Chief Scientific Officer, Dr. Sazzad Hossain states, "We believe the development of this delivery system will position InMed to increase efficacies of our therapies as well as open additional industry opportunities for licensing and collaboration in other disease areas. We are fortunate to have created this alliance with Dr. Yadav, the principal investigator of this project."

Dr. Yadav was most recently with the Department of Chemistry and Chemical Biology at Harvard University and the Department of Chemical Engineering at Massachusetts Institute of Technology. Dr. Yadav and his team will be conducting this project from their state-of-the-art laboratory at the University of British Columbia's Chemical and Biological Engineering Department.

"Strategically we view our first academic partnership as highly complementary to our existing drug discovery and development efforts," says Craig Schneider, President & CEO. "Given the broad potential of this drug delivery system, it was critical to us to work closely with a leading academic institution. We are honored to be partnering with one of the world's premier academic medical research institutions."

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMeds' Proprietary Platform Technology, Product pipeline and accelerated development pathway are the fundamental value drivers of the Company.

ON BEHALF OF THE BOARD

InMed Pharmaceuticals Inc.

Craig Schneider, President and Chief Executive Officer

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information